Blueprint Medicines Corporation
BPMC
Rang in Aktien
#2358
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Aktienkurs
$129.46
Zuletzt synchronisiert: 2025-07-18
Marktkapitalisierung
$8.36B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Blueprint Medicines Corporation (BPMC)
Kategorie
Healthcare
Operative Marge für Blueprint Medicines Corporation (BPMC)
Operative Marge zum October 2026 TTM: -41.67%
Laut den neuesten Finanzberichten und dem Aktienkurs von Blueprint Medicines Corporation beträgt die aktuelle operative Marge (TTM) -41.67%. Am Ende des Jahres 2023 lag die operative Marge bei -194.99%.
Historie der operativen Marge von Blueprint Medicines Corporation von 2013 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | -41.67% | 0.00% |
| 2024 | -41.67% | -78.63% |
| 2023 | -194.99% | -27.56% |
| 2022 | -269.19% | -25.25% |
| 2021 | -360.10% | -1,045.89% |
| 2020 | 38.07% | -106.91% |
| 2019 | -551.16% | -0.67% |
| 2018 | -554.86% | -20.47% |
| 2017 | -697.64% | 163.22% |
| 2016 | -265.04% | -43.01% |
| 2015 | -465.10% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -100.93% |
US
|
|
| -149.01% | -96.42% |
US
|
|
| 25.57% | -100.61% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.69% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.